Physician profile
Paul Coleman
NPI 1104934645
$1,357.43
in general payments reported to CMS, 2019-2025
23 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $143 · 2022: $170 · 2023: $160 · 2024: $328 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $235.58 | 2022-2025 | Ubrelvy |
| Pfizer INC. | $172.06 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $143.95 | 2019 | |
| Glaxosmithkline, LLC. | $98.67 | 2020-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbott Laboratories | $87.38 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $72.45 | 2020-2025 | Airsupra, Breztri |
| Amgen INC. | $66.06 | 2020-2024 | Krystexxa |
| Corcept Therapeutics | $62.10 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $48.86 | 2020-2024 | Veozah |
| Merck Sharp & Dohme LLC | $40.71 | 2020-2025 | Capvaxive, Gardasil 9, Proquad |
| Phathom Pharmaceuticals, INC. | $40.06 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $37.76 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.65 | 2024 | Xifaxan, Trulance |
| Optinose US, INC. | $36.06 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.29 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30.00 | 2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $23.62 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $22.35 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $16.20 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.45 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.17 | 2023 | Livalo, Seglentis |
| Lilly USA, LLC | $13.13 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.